Amil M Shah1, Brian Claggett2, Nancy K Sweitzer2, Sanjiv J Shah2, Inder S Anand2, Eileen O'Meara2, Akshay S Desai2, John F Heitner2, Guichu Li2, James Fang2, Jean Rouleau2, Michael R Zile2, Valetin Markov2, Vyacheslav Ryabov2, Gilmar Reis2, Susan F Assmann2, Sonja M McKinlay2, Bertram Pitt2, Marc A Pfeffer2, Scott D Solomon2. 1. From the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.M.S., B.C., A.S.D., G.L., M.A.P., S.D.S.); University of Wisconsin Hospital and Clinics, Madison (N.K.S.); Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); VA Medical Center, Minneapolis, MN (I.S.A.); Montreal Heart Institute, Montreal, Canada (E.O., J.R.); New York Methodist Hospital, Brooklyn (J.F.H.); University of Utah School of Medicine, Salt Lake City (J.F.); Medical University of South Carolina, Charleston (M.R.Z.); Research Cardiology Institute Tomsk Scientific Center, Tomsk, Russia (V.M., V.R.); Santa Casa de Belo Horizonte, Belo Horizonte, Brazil (G.R.); New England Research Institutes, Watertown, MA (S.F.A., S.M.M.); and University of Michigan School of Medicine, Ann Arbor (B.P.). ashah11@partners.org. 2. From the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.M.S., B.C., A.S.D., G.L., M.A.P., S.D.S.); University of Wisconsin Hospital and Clinics, Madison (N.K.S.); Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.); VA Medical Center, Minneapolis, MN (I.S.A.); Montreal Heart Institute, Montreal, Canada (E.O., J.R.); New York Methodist Hospital, Brooklyn (J.F.H.); University of Utah School of Medicine, Salt Lake City (J.F.); Medical University of South Carolina, Charleston (M.R.Z.); Research Cardiology Institute Tomsk Scientific Center, Tomsk, Russia (V.M., V.R.); Santa Casa de Belo Horizonte, Belo Horizonte, Brazil (G.R.); New England Research Institutes, Watertown, MA (S.F.A., S.M.M.); and University of Michigan School of Medicine, Ann Arbor (B.P.).
Abstract
BACKGROUND: Abnormalities in cardiac structure and function in heart failure with preserved ejection fraction may help identify patients at particularly high risk for cardiovascular morbidity and mortality. METHODS AND RESULTS: Cardiac structure and function were assessed by echocardiography in a blinded core laboratory at baseline in 935 patients with heart failure with preserved ejection fraction (left ventricular ejection fraction ≥45%) enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial and related to the primary composite outcome of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest, and its components. At a median follow-up of 2.9 years, 244 patients experienced the primary outcome. Left ventricular hypertrophy (adjusted hazard ratio, 1.52; 95% confidence interval, 1.16-2.00), elevated left ventricular filling pressure (E/E'; adjusted hazard ratio 1.05 per 1 integer increase; 95% confidence interval, 1.02-1.07), and higher pulmonary artery pressure assessed by the tricuspid regurgitation velocity (hazard ratio, 1.23 per 0.5 m/s increase; 95% confidence interval, 1.02-1.49) were associated with the composite outcome and heart failure hospitalization alone after adjusting for clinical and laboratory variables. The risk of adverse outcome associated with left ventricular hypertrophy was additive to the risk associated with elevated E/E'. CONCLUSIONS: Among heart failure with preserved ejection fraction patients enrolled in TOPCAT, left ventricular hypertrophy, higher left ventricular filling pressure, andhigher pulmonary artery pressure were predictive of heart failure hospitalization, cardiovascular death, or aborted cardiac arrest independent of clinical and laboratory predictors. These features, both alone and in combination, identify heart failure with preserved ejection fraction patients at particularly high risk for cardiovascular morbidity and mortality. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.
RCT Entities:
BACKGROUND: Abnormalities in cardiac structure and function in heart failure with preserved ejection fraction may help identify patients at particularly high risk for cardiovascular morbidity and mortality. METHODS AND RESULTS: Cardiac structure and function were assessed by echocardiography in a blinded core laboratory at baseline in 935 patients with heart failure with preserved ejection fraction (left ventricular ejection fraction ≥45%) enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial and related to the primary composite outcome of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest, and its components. At a median follow-up of 2.9 years, 244 patients experienced the primary outcome. Left ventricular hypertrophy (adjusted hazard ratio, 1.52; 95% confidence interval, 1.16-2.00), elevated left ventricular filling pressure (E/E'; adjusted hazard ratio 1.05 per 1 integer increase; 95% confidence interval, 1.02-1.07), and higher pulmonary artery pressure assessed by the tricuspid regurgitation velocity (hazard ratio, 1.23 per 0.5 m/s increase; 95% confidence interval, 1.02-1.49) were associated with the composite outcome and heart failure hospitalization alone after adjusting for clinical and laboratory variables. The risk of adverse outcome associated with left ventricular hypertrophy was additive to the risk associated with elevated E/E'. CONCLUSIONS: Among heart failure with preserved ejection fraction patients enrolled in TOPCAT, left ventricular hypertrophy, higher left ventricular filling pressure, and higher pulmonary artery pressure were predictive of heart failure hospitalization, cardiovascular death, or aborted cardiac arrest independent of clinical and laboratory predictors. These features, both alone and in combination, identify heart failure with preserved ejection fraction patients at particularly high risk for cardiovascular morbidity and mortality. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: V Dall'Aglio; G D'Angelo; E Moro; G L Nicolosi; C Burelli; F Zardo; E Cervesato; D Zanuttini Journal: Eur Heart J Date: 1989-04 Impact factor: 29.983
Authors: Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: R B Devereux; M J Roman; J E Liu; T K Welty; E T Lee; R Rodeheffer; R R Fabsitz; B V Howard Journal: Am J Cardiol Date: 2000-11-15 Impact factor: 2.778
Authors: Deepak K Gupta; Amil M Shah; Davide Castagno; Madoka Takeuchi; Laura R Loehr; Ervin R Fox; Kenneth R Butler; Thomas H Mosley; Dalane W Kitzman; Scott D Solomon Journal: JACC Heart Fail Date: 2013-04 Impact factor: 12.035
Authors: Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald Journal: JAMA Date: 2013-03-27 Impact factor: 56.272
Authors: Kun-Lun He; Daniel Burkhoff; Wen-Xiu Leng; Zhi-Ru Liang; Li Fan; Jie Wang; Mathew S Maurer Journal: Am J Cardiol Date: 2009-03-15 Impact factor: 2.778
Authors: Dirk Westermann; Mario Kasner; Paul Steendijk; Frank Spillmann; Alexander Riad; Kerstin Weitmann; Wolfgang Hoffmann; Wolfgang Poller; Matthias Pauschinger; Heinz-Peter Schultheiss; Carsten Tschöpe Journal: Circulation Date: 2008-04-14 Impact factor: 29.690
Authors: C G Chen; J D Thomas; J Anconina; P Harrigan; L Mueller; M H Picard; R A Levine; A E Weyman Journal: Circulation Date: 1991-08 Impact factor: 29.690
Authors: Jennifer E Ho; Emily K Zern; Luke Wooster; Cole S Bailey; Thomas Cunningham; Aaron S Eisman; Kathryn M Hardin; Giovanna A Zampierollo; Petr Jarolim; Paul P Pappagianopoulos; Rajeev Malhotra; Matthew Nayor; Gregory D Lewis Journal: Circulation Date: 2019-05-28 Impact factor: 29.690
Authors: Angela B S Santos; Gabriela Querejeta Roca; Brian Claggett; Nancy K Sweitzer; Sanjiv J Shah; Inder S Anand; James C Fang; Michael R Zile; Bertram Pitt; Scott D Solomon; Amil M Shah Journal: Circ Heart Fail Date: 2016-04 Impact factor: 8.790
Authors: Michael R Zile; Pardeep S Jhund; Catalin F Baicu; Brian L Claggett; Burkert Pieske; Adriaan A Voors; Margaret F Prescott; Victor Shi; Martin Lefkowitz; John J V McMurray; Scott D Solomon Journal: Circ Heart Fail Date: 2016-01 Impact factor: 8.790
Authors: Amil M Shah; Brian Claggett; Dalane Kitzman; Tor Biering-Sørensen; Jan Skov Jensen; Susan Cheng; Kunihiro Matsushita; Suma Konety; Aaron R Folsom; Thomas H Mosley; Jacqueline D Wright; Gerardo Heiss; Scott D Solomon Journal: Circulation Date: 2016-12-07 Impact factor: 29.690
Authors: Amil M Shah; Brian Claggett; Nancy K Sweitzer; Sanjiv J Shah; Anita Deswal; Inder S Anand; Jerome L Fleg; Bertram Pitt; Marc A Pfeffer; Scott D Solomon Journal: Circ Heart Fail Date: 2015-10-16 Impact factor: 8.790